{'fraction_non_alphanumeric': 0.02763018065887354, 'fraction_numerical': 0.011689691817215728, 'mean_word_length': 6.029850746268656, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Risperidone for Treatment-Resistant Schizophrenia: Initial Clinical Experience in a State Hospital

Objective: To examine the efficacy of risperidone, a new antipsychotic with combined serotonergic-dopaminergic antagonism, in patients with treatment-resistant schizophrenia in state facilities. Methods: Brief Psychiatric Rating Scale (BPRS) evaluations were performed on 21 patients with schizophrenia who had received risperidone therapy for 10 weeks in a state facility. Results: Five patients showed a 20% reduction on their pretreatment BPRS score. A corresponding number of patients showed an increased BPRS score during treatment, and the remainder attained a modest reduction (2–17%) in symptoms on the BPRS. Conclusions: Although risperidone was an effective antipsychotic for patients with chronic treatment-resistant schizophrenia, only a subgroup of these patients achieved substantial clinical improvement over a 10-week period.